Analysts Expect Iradimed Corp (IRMD) to Announce ($0.02) Earnings Per Share

Analysts Expect Iradimed Corp (IRMD) to Announce ($0.02) Earnings Per Share

Iradimed Corp (NASDAQ:IRMD) has earned an average broker rating score of 3.00 (Hold) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a hold rating.

Analysts have set a 12 month consensus price objective of $10.25 for the company and are anticipating that the company will post ($0.02) earnings per share for the current quarter, according to Zacks. Zacks has also given Iradimed Corp an industry rank of 99 out of 265 based on the ratings given to its competitors.

Several equities research analysts recently issued reports on the company. Zacks Investment Research upgraded Iradimed Corp from a “sell” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Tuesday, December 6th. TheStreet cut Iradimed Corp from a “c-” rating to a “d+” rating in a report on Monday, January 23rd.

In other Iradimed Corp news, CEO Roger E. Susi bought 10,000 shares of the firm’s stock in a transaction on Thursday, February 9th. The shares were acquired at an average cost of $8.60 per share, with a total value of $86,000.00. Following the purchase, the chief executive officer now directly owns 15,000 shares of the company’s stock, valued at approximately $129,000. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 69.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC raised its position in Iradimed Corp by 99.0% in the third quarter. Conestoga Capital Advisors LLC now owns 572,885 shares of the company’s stock worth $9,733,000 after buying an additional 285,050 shares during the period. Mondrian Investment Partners LTD raised its position in Iradimed Corp by 73.0% in the third quarter. Mondrian Investment Partners LTD now owns 135,729 shares of the company’s stock worth $2,306,000 after buying an additional 57,272 shares during the period. AQR Capital Management LLC raised its position in Iradimed Corp by 97.7% in the fourth quarter. AQR Capital Management LLC now owns 109,318 shares of the company’s stock worth $1,213,000 after buying an additional 54,011 shares during the period. Grandeur Peak Global Advisors LLC acquired a new position in Iradimed Corp during the third quarter worth $1,817,000. Finally, Wasatch Advisors Inc. raised its position in Iradimed Corp by 15.5% in the third quarter. Wasatch Advisors Inc. now owns 97,000 shares of the company’s stock worth $1,648,000 after buying an additional 13,000 shares during the period. 22.86% of the stock is currently owned by institutional investors and hedge funds.

Shares of Iradimed Corp (NASDAQ:IRMD) remained flat at $8.10 on Wednesday. The company had a trading volume of 2,139 shares. Iradimed Corp has a 52-week low of $7.85 and a 52-week high of $22.53. The company has a market capitalization of $86.81 million, a PE ratio of 13.50 and a beta of 1.66. The stock has a 50-day moving average of $8.73 and a 200 day moving average of $11.52.

Iradimed Corp (NASDAQ:IRMD) last posted its quarterly earnings data on Monday, February 6th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.07. Iradimed Corp had a return on equity of 24.50% and a net margin of 22.20%. The company had revenue of $6 million for the quarter, compared to analysts’ expectations of $6.09 million. During the same period in the previous year, the firm posted $0.19 EPS. Iradimed Corp’s revenue was down 31.9% compared to the same quarter last year. On average, equities research analysts anticipate that Iradimed Corp will post $0.16 EPS for the current fiscal year.

About Iradimed Corp

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get a free copy of the Zacks research report on Iradimed Corp (IRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment